Max Parisi seeks FDA-approved pancreatic cancer drug in the U.S

Radio host Max Parisi has traveled to the United States to access daraxonrasib, a new drug recently approved by the U.S. Food and Drug Administration (FDA) for treating specific molecular alterations in pancreatic cancer.

After being told in July that no further therapeutic options remained, Parisi sought the treatment in America. While the drug is available for clinical use in the U.S., oncologist Chiara Cremolini notes that it is not yet approved by the European Medicines Agency (EMA). Consequently, the medication is not reimbursed by public health systems in Europe and must be purchased privately by patients.

Parisi, who has faced significant weight loss and metastatic complications, expressed hope that the therapy might extend his life through the end of the year.